Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study

Maria Gabriella Ferrandina, Giovanni Scambia, Bruno Vincenzi, Marco Marinaccio, Emanuele Naglieri, Vera Loizzi, Silvia Carpano, Giuseppe Tonini, Domenica Lorusso

Risultato della ricerca: Contributo in rivistaArticolo in rivista

16 Citazioni (Scopus)

Abstract

The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis) in very heavily treated, relapsed ovarian cancer (ROC) patients.
Lingua originaleEnglish
pagine (da-a)505-510
Numero di pagine6
RivistaGynecologic Oncology
Volume130
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Adult
  • Aged
  • Alanine Transaminase
  • Antineoplastic Agents, Alkylating
  • Aspartate Aminotransferases
  • Asthenia
  • Carcinoma
  • Dioxoles
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Middle Aged
  • Neutropenia
  • Ovarian Neoplasms
  • Ovarian cancer
  • Platinum Compounds
  • Retrospective Studies
  • Salvage Therapy
  • Salvage treatment
  • Tetrahydroisoquinolines
  • Trabectedin

Fingerprint

Entra nei temi di ricerca di 'Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study'. Insieme formano una fingerprint unica.

Cita questo